Camila Simões Freitas

Ms. Camila Simões Freitas

UFMG, Belo Horizonte, Minas Gerais, Brazil
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
DLDaniela P. Lage
Daniela P. Lage
DVDanniele L. Vale
Danniele L. Vale
FLFlávia P. Linhares
Flávia P. Linhares
CFCamila Simões Freitas
Camila Simões Freitas
AMAmanda S. Machado
Amanda S. Machado
VMVívian T. Martins
Vívian T. Martins
Currently, there is no licensed vaccine to protect against human visceral leishmaniasis (VL), a potentially fatal disease caused by infection with Leishmania parasites. In the current study, a recombinant chimeric protein ChimT was developed based on T-cell epitopes identified from the immunogenic Leishmania amastigote proteins LiHyp1, LiHyV, LiHyC and LiHyG. ChimT was associated with the adjuvants saponin (Sap) or monophosphoryl lipid A (MPLA) and used to immunize mice, and their immunogenicity and protective efficacy were evaluated. Both ChimT/Sap and ChimT/MPLA induced the development of a specific Th1-type immune response, with significantly high levels of IFN-γ, IL-2, IL-12, TNF-α and GM-CSF cytokines produced by CD4+ and CD8+ T cell subtypes (p < 0.05), with correspondingly low production of anti-leishmanial IL-4 and IL-10 cytokines. Significantly increased (p < 0.05) levels of nitrite, a proxy for nitric oxide, and IFN-γ expression (p < 0.05) were detected in stimulated spleen cell cultures from immunized and infected mice, as was significant production of parasite-specific IgG2a isotype antibodies. Significant reductions in the parasite load in the internal organs of the immunized and infected mice (p < 0.05) were quantified with a limiting dilution technique and quantitative PCR and correlated with the immunological findings. ChimT/MPLA showed marginally superior immunogenicity than ChimT/Sap, and although this was not statistically significant (p > 0.05), ChimT/MPLA was preferred since ChimT/Sap induced transient edema in the inoculation site. ChimT also induced high IFN-γ and low IL-10 levels from human PBMCs isolated from healthy individuals and from VL-treated patients. In conclusion, the experimental T-cell multi-epitope amastigote stage Leishmania vaccine administered with adjuvants appears to be a promising vaccine candidate to protect against VL.

9 June 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
DLDaniela P. Lage
Daniela P. Lage
PRPatrícia A.F. Ribeiro
Patrícia A.F. Ribeiro
DDDaniel S. Dias
Daniel S. Dias
DMDébora V.C. Mendonça
Débora V.C. Mendonça
FRFernanda Fonseca Ramos
Fernanda Fonseca Ramos
ECEDUARDO COELHO
EDUARDO COELHO
Background: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation. Methods: BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo. Results: Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels. Conclusions: Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL.

18 April 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
BSBianca De Melo Santana
Bianca De Melo Santana
GAGiovana Marchini Armentano
Giovana Marchini Armentano
DFDayana Agnes Santos Ferreira
Dayana Agnes Santos Ferreira
CFCamila Simões Freitas
Camila Simões Freitas
MCMarcela Sorelli Carneiro-Ramos
Marcela Sorelli Carneiro-Ramos
MCMyron Christodoulides
Myron Christodoulides

1 January 2022 in Microbial Pathogenesis
Verified
Journal Article
Closed access
NGNathalia C. Galvani
Nathalia C. Galvani
AMAmanda S. Machado
Amanda S. Machado
DLDaniela P. Lage
Daniela P. Lage
VMVívian T. Martins
Vívian T. Martins
DODaysiane de Oliveira
Daysiane de Oliveira
ECEDUARDO COELHO
EDUARDO COELHO

16 March 2022 in Acta Tropica
Verified
Journal Article
Closed access
AMAmanda S. Machado
Amanda S. Machado
DLDaniela P. Lage
Daniela P. Lage
DVDanniele L. Vale
Danniele L. Vale
CFCamila Simões Freitas
Camila Simões Freitas
FLFlávia P. Linhares
Flávia P. Linhares
ECEDUARDO COELHO
EDUARDO COELHO

2 May 2022 in Microbial Pathogenesis
Verified
Journal Article
Closed access
DVDanniele L. Vale
Danniele L. Vale
AMAmanda S. Machado
Amanda S. Machado
FRFernanda F. Ramos
Fernanda F. Ramos
DLDaniela P. Lage
Daniela P. Lage
CFCamila Simões Freitas
Camila Simões Freitas
ECEDUARDO COELHO
EDUARDO COELHO